HFA
APLS

Hoover Financial Advisors’s Apellis Pharmaceuticals APLS Stock Holding History

Hoover Financial Advisors’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		$6K Hold
100
– – ﹤0.01% 520
2021
Q1 		$5K Buy
+100
New +$4.73K ﹤0.01% 490

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Hoover Financial Advisors's APLS Position: Q2 2021 in Review

Hoover Financial Advisors held its Apellis Pharmaceuticals (APLS) position steady in Q2 2021 at 100 shares worth $6K. The position accounts for ﹤0.01% of the portfolio, ranked #520.

Hoover Financial Advisors first reported a position in APLS in Q1 2021 and has held it in 2 quarters since. 204 funds tracked by Wall St. Rank hold APLS as of Q2 2021.

  • Hoover Financial Advisors held 100 shares of Apellis Pharmaceuticals worth $6K as of Q2 2021.
  • Hoover Financial Advisors left its Apellis Pharmaceuticals share count unchanged in Q2 2021.
  • Apellis Pharmaceuticals made up ﹤0.01% of Hoover Financial Advisors's portfolio in Q2 2021, its #520 holding.
  • Hoover Financial Advisors first reported a position in Apellis Pharmaceuticals in Q1 2021 and has held it in 2 quarters since.
  • 204 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2021.

Based on Hoover Financial Advisors's 13F filing for Q2 2021, filed 28 Jul 2021.